Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

(2009) E. Jabbour et al.   BLOOD

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cellsin vitro

(2009) Brigitte Kircher et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

(2009) Clara I. Aceves-Luquero et al.   PLoS One

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

(2008) T. P. Hughes et al.   BLOOD

EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation

(2008) F. Bouilloux et al.   BLOOD

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

(2008) C. S. Tam et al.   BLOOD

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

(2008) E. Jabbour et al.   BLOOD

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

(2008) J. Wu et al.   BLOOD

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

(2008) A. Gontarewicz et al.   BLOOD

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

(2008) E. Jabbour et al.   BLOOD

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

(2008) T.-S. Lee et al.   MOLECULAR CANCER THERAPEUTICS